Market Intelligence, Clinical Progress, and High-Purity Reagents for NKG2D Axis Modulation
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for ULBP1 drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | ULBP1 ECD-Fc / His Fusion Protein HEK293 Expressed (Native Glycosylation), High Purity (>95%), Endotoxin <1EU/µg. Sequence Verified. |
View ULBP1 Products |
| Gene Delivery | ULBP1 Lentivirus / Promise-ORF Premade Particles Full-length ORF for stable cell lines. Cell-based assays for preserved conformation. Internalization-ready. |
View ULBP1 Products |
| Benchmark Ab | Anti-ULBP1 Neutralizing / Benchmark Antibody Recombinant monoclonal positive control. Sequence Verified. |
View ULBP1 Products |
| Validator | ULBP1 siRNA Set For knockdown verification and specificity controls. |
View ULBP1 Products |
| Related Target: ULBP2 | ULBP2 (NKG2D Ligand Family) Homology member for cross-reactivity and selectivity screening. |
View ULBP2 Products |
| Related Target: MICA | MICA (MHC Class I Chain-Related A) Parallel NKG2D ligand for comparative binding studies. |
View MICA Products |
| Related Target: NKG2D | NKG2D (KLRK1) Receptor Counter-receptor for interaction assays. |
View NKG2D Products |
Critical Assay Challenges & Specifications
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Ligand Selectivity & Subfamily Counter Screening (ULBP1 vs ULBP2/3/4) | Strictly Verified Homolog Panel: ULBP1, ULBP2, ULBP3, ULBP4 proteins distinguished by Mass Spec; >95% purity eliminates cross-reactivity artifacts. |
| Species Cross-Reactivity (Human/Cyno/Mouse) | Ortholog Protein Pairs Available: Human and Cynomolgus ULBP1 ECD-Fc with sequence-verified extracellular domains. |
| Proper Glycosylation for Receptor Binding | HEK293 Expressed (Native Glycosylation), maintaining natural structural integrity for accurate binding studies. |
| GPI-Anchor Shedding Detection | Full-Length Lentivirus System: Presents native GPI-anchored topology for metalloproteinase cleavage assays. |
| Receptor Binding Affinity (NKG2D) | SPR-Grade ECD-Fc: Low endotoxin (<1 EU/µg), monodisperse by SEC-MALS for accurate kinetic measurements. |
| Target Validation & False Positive Control | Validated ULBP1 siRNA Set included for specificity checks in cellular assays. |
Live ULBP1 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for NKG2D axis therapeutics is intensifying, with major players shifting focus from systemic cytokine administration to targeted modulation of stress-induced ligands. As first-generation NKG2D receptor antibodies advance through Phase II, the next wave of R&D is targeting ULBP1-specific shedding inhibition, CAR-NK cell engineering, and multi-specific NK cell engagers (e.g., targeting NKG2D and CD16A). The therapeutic paradigm diverges between oncology (preserving ULBP1-NKG2D engagement to drive tumor cell killing) and autoimmunity (blocking the axis to prevent tissue damage). High expression of ULBP1 in various solid and hematological malignancies, but absence in most normal tissues, makes it an attractive target for immunotherapy.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Anti-Shedding mAb | Oncology Biotechs | Solid Tumors | Shedding Assay (Need full-length GPI-anchored ULBP1 lentivirus) |
| Blocking Antibody | Autoimmune Specialists | Rheumatoid Arthritis, IBD | Receptor Competition Assay (Need high-affinity ULBP1 ECD) |
| Soluble Receptor Decoy (NKG2D-Fc) | Immunotherapy Developers | Metastatic Cancer | Ligand Binding Panel (Need ULBP1/2/3 + MICA/B homolog set) |
| NK Cell Engagers (Tri-specifics) | Innate Pharma, Sanofi | Solid Tumors, AML | Receptor Binding Assay (Need high-purity HEK293 expressed antigens) |
| CAR-NK / CAR-T | Nkarta Therapeutics, Celyad | Hematologic Malignancies | Cell Surface Expression (Need stable ULBP1+ target cells via lentivirus) |
| Monoclonal Antibodies (General) | Early Stage Biotech | Refractory Cancers | Epitope Mapping (Need specific ECD truncations & High Purity >95%) |